Volume 25, Issue 3 pp. 253-259
Research Article

Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients

Arun K. Tiwari

Arun K. Tiwari

Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Search for more papers by this author
Clement C. Zai

Clement C. Zai

Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Search for more papers by this author
Herbert Y. Meltzer

Herbert Y. Meltzer

Psychiatric Hospital at Vanderbilt University, Nashville, Tennessee, USA

Search for more papers by this author
Jeffrey A. Lieberman

Jeffrey A. Lieberman

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York City, New York, USA

Search for more papers by this author
Daniel J. Müller

Daniel J. Müller

Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Search for more papers by this author
James L. Kennedy

Corresponding Author

James L. Kennedy

Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

R-30, Neurogenetics Section, Center for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada.Search for more papers by this author
First published: 30 March 2010
Citations: 28

Conflict of interest: AKT/CCZ/DJM report no competing interests. HYM has received grants or is a consultant to: Abbott Labs, ACADIA, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Astra Zeneca, Glaxo Smith Kline, Memory, Cephalon, Minster, Aryx and BiolineRx. HYM is a shareholder of ACADIA. JAL reports having received research funding or consulting or educational fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Novartis, Pfizer and Solvay. JLK has been a consultant to GSK, Sanofi-Aventis, Dainippon-Sumitomo.

Abstract

Objective

Atypical antipsychotic drugs, in particular clozapine and olanzapine, influence cellular lipogenesis and are associated with metabolic side effects including weight gain. Insulin induced gene 2 (INSIG2) mediates feedback control of lipid synthesis and polymorphisms in the gene (rs17587100, rs10490624 and rs17047764) have been associated with antipsychotic induced weight gain. In this study we intended to replicate these findings in an independent patient population.

Methods

All three polymorphisms as well as an additional polymorphism (rs7566605) were genotyped in 154 patients who underwent treatment for chronic schizophrenia with one of four antipsychotics (clozapine, olanzapine, haloperidol or risperidone). Patients were evaluated for antipsychotic induced weight gain during treatment for up to 14 weeks.

Results

We did not observe any significant allelic, genotypic or haplotypic association of the polymorphisms with antipsychotic induced weight gain in the patients of European ancestry (p > 0.05). In the patients of African ancestry, no haplotypic association was observed but a trend of allelic association with the C allele of rs7566605 and genotypic association with the ‘GC’ genotype in rs17047764 was observed (p = 0.02; pBonferroni = 0.225).

Conclusion

We were unable to replicate significant associations in patients of European ancestry. However, we observed a marginal effect of the rs17047764 and rs7566605 in the African-American sample. Since the latter observations were generated in a relatively small sample set, further replication studies are warranted. Copyright © 2010 John Wiley & Sons, Ltd.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.